DOTAP/DC-CHOL Cationic Liposomes
Product code:F50101V
Lipid composition: DOTAP/DC-Cholesterol (50:50 mol/mol)
Mean particle size:50-80 nm (by DSL)
Lipid concentration: 40 mM (24.7 mg/mL)
Volume:2.0mL
Bulk solution:D5W (dextrose in milli-Q water)
Shelf-life:6 monthsguaranteed for sterility for unopened vials stored at 2-8 degree C (guaranteedstarting from the date of delivery, replacement only)
DOTAP:1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)
DC-CHOL:DC-Cholesterol∙HCl, 3b-[N-(N",N"-dimethylaminoethane)-caramoyl]chelesterol hydrochloride
Attachment of class B CpG ODN ontoDOTAP/DC-cholliposomein nasalvaccineformulations augments antigen-specificimmuneresponses in mice.
Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2017 Jan 26;10(1):68. doi: 10.1186/s13104-017-2380-8.PMID:28126014
Nasalvaccinationwith pneumococcal surface protein A in combination with cationicliposomesconsisting ofDOTAPandDC-cholconfers antigen-mediated protectiveimmunityagainst Streptococcus pneumoniae infections in mice.
Tada R, Suzuki H, Takahashi S, Negishi Y, Kiyono H, Kunisawa J, Aramaki Y.Int Immunopharmacol. 2018 Aug;61:385-393.
Comparison of the depot effect and immunogenicity ofliposomesbased on dimethyldioctadecylammonium (DDA), 3β-[N-(N",N"-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolongedliposomeretention mediates stronger Th1 responses.
Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, Perrie Y.Mol Pharm. 2011 Feb 7;8(1):153-61.
Cationic DDA/TDBliposomeas a mucosalvaccineadjuvant for uptake by dendritic cells in vitro induces potent humouralimmunity.
Qu W, Li N, Yu R, Zuo W, Fu T, Fei W, Hou Y, Liu Y, Yang J.Artif Cells Nanomed Biotechnol. 2018;46(sup1):852-860.
IntranasalImmunizationwithDOTAPCationicLiposomesCombined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and SystemicImmuneResponses in Mice.
Tada R, Hidaka A, Iwase N, Takahashi S, Yamakita Y, Iwata T, Muto S, Sato E, Takayama N, Honjo E, Kiyono H, Kunisawa J, Aramaki Y.PLoS One. 2015 Oct 6;10(10):e0139785. doi: 10.1371/journal.pone.0139785. eCollection 2015.PMID:26440657
Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K, Sundaresan A, Cheow WS.Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43.
Intranasal administration of cationicliposomesenhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.
Tada R, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.BMC Res Notes. 2018 Jul 13;11(1):472.
Predicting the influence ofliposomallipid composition onliposomesize, zeta potential andliposome-induced dendritic cell maturation using a design of experiments approach.
Soema PC, Willems GJ, Jiskoot W, Amorij JP, Kersten GF.Eur J Pharm Biopharm. 2015 Aug;94:427-35.
Liposome-mediated DNAimmunisationvia the subcutaneous route.
Perrie Y, McNeil S, Vangala A.J Drug Target. 2003;11(8-10):555-63.
Lipoplexes formulation and optimisation: in vitro transfection studies reveal no correlation with in vivovaccinationstudies.
McNeil SE, Vangala A, Bramwell VW, Hanson PJ, Perrie Y.Curr Drug Deliv. 2010 Apr;7(2):175-87.
A new intranasal influenzavaccinebased on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.Vaccine. 2006 May 1;24(18):3990-4006.
Cationicliposomespromote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens.
Gao J, Ochyl LJ, Yang E, Moon JJ.Int J Nanomedicine. 2017 Feb 14;12:1251-1264.
Transcutaneousimmunizationby lipoplex-patch based DNAvaccinesis effectivevaccinationagainst Japanese encephalitis virus infection.
Cheng JY, Huang HN, Tseng WC, Li TL, Chan YL, Cheng KC, Wu CJ.J Control Release. 2009 May 5;135(3):242-9.
